Targeted Drug Assay
The PharmaFlow platform in combination with molecular analysis allows screening of agents that specifically target cellular mechanisms or pathways. Agents like inhibitors of tyrosine-kinase receptors (TKR), farnesyl-transferase inhibitors (FTI), mitogen activated protein kinase (MAPK), inhibitors mammalian target of rapamycin (mTOR) and AKT inhibitors; drugs that interfere with the cell cycle—ie, cyclin-dependent kinase (CDK) inhibitors and aurorakinase inhibitors; inhibitors of the unfolded protein response (UPR)—ie, heat-shock protein (HSP) inhibitors, proteasome inhibitors, or epigenetic agents. According to their specific mechanism of action, the appropriate readout is applied to each compound in our Native Environment Assays.
Tubeandbracket
  • AML
  • CLL
  • MM
Native Blook Cell Populations
  • Red Blood Cells
  • Platelets
  • Neutrophils
  • AML / CLL / MM Leukemic Cells
  • Lymphocytes
  • Others

Target Drug
Cytotoxic Drug Therapy
Plate Cytotoxic Drug

Hematological
Sample

Native Cell
Population

Targeted Drug
Incubation

Cells Retrieval &
FCM Readout

Targeted Drug Assay:
Native Environment

005 Targeted Drug Assay (Venetoclax)
Hematological
Sample
Tubeandbracket
  • AML
  • CLL
  • MM
Native Cell Population
Native Blook Cell Populations
  • Red Blood Cells
  • Platelets
  • Neutrophils
  • AML / CLL / MM Leukemic Cells
  • Lymphocytes
  • Others
Targeted Drug Incubation
Target Drug
Cytotoxic Drug Therapy
Cells Retrieval & FCM Readout
Plate Cytotoxic Drug
Targeted Drug Assay:
Native Environment
005 Targeted Drug Assay (Venetoclax)